Abstract
To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy (age 12 years and older).
To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy (age 12 years and older).
Stanley Manne Children's Research Institute
Louis A. Simpson and Kimberly K. Querrey Biomedical Research Center
303 East Superior Street
Chicago, IL 60611
